Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06129851 · ClinicalTrials.gov registry record · Phase 2
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT06129851 is a Phase 2 study that has not yet begun recruiting, run by University of Kansas Medical Center. The registered enrollment target is 90 participants.
The verdict
NCT06129851, a Phase 2 study, has not yet begun recruiting, sponsored by University of Kansas Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This phase II trial evaluates the best duration for relugolix to be given in combination with radiation therapy when treating patients with high risk prostate cancer. Prostate cancer is a hormonal influenced cancer. Part of the usual treatment for patients with prostate cancer is androgen deprivation therapy (ADT). ADT is used to lower the amount of testosterone in the body, because testosterone appears to help prostate cancer grow. Relugolix works to reduce testosterone levels, which may inhibit proliferation of prostate cancer cells. It is approved by the Food and Drug Administration to treat prostate cancer. Adding relugolix to standard radiation therapy might work better and have fewer side effects than prior forms of hormonal therapy, but the optimal duration of relugolix in combination with radiation is not known.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- RADIATION Brachytherapy
- PROCEDURE Bone Scan
- PROCEDURE Dual X-ray Absorptiometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2026-10-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06129851
The ClinicalTrials.gov registry entry for NCT06129851 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06129851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06129851 about?
NCT06129851 is a clinical study titled "Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer". This phase II trial evaluates the best duration for relugolix to be given in combination with radiation therapy when treating patients with high risk prostate cancer. Prostate cancer is a hormonal influenced cancer. Part of the usual treatment for patients with prostate cancer is androgen deprivatio...
What is the current status of trial NCT06129851?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2023-11-20. Estimated completion is 2026-10-23.
What interventions are being tested in trial NCT06129851?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Brachytherapy (RADIATION), Bone Scan (PROCEDURE), Dual X-ray Absorptiometry (PROCEDURE).
Who is sponsoring clinical trial NCT06129851?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.